Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christian T Ruff

Showing results (101-110 of 193) with videos related to

Pageof 20
Sort By:
European Heart Journal|February 18, 2015
Edoxaban vs. warfarin in vitamin K antagonist experienced and naive patients with atrial fibrillation†Michelle L O'Donoghue, Christian T Ruff, Robert P Giugliano, et al.
Circulation|October 11, 2019
Comparison of Events Across Bleeding Scales in the ENGAGE AF-TIMI 48 TrialBrian A Bergmark, Pieter W Kamphuisen, Stephen D Wiviott, et al.
JAMA Cardiology|July 10, 2024
Dose Reduction of Edoxaban in Patients 80 Years and Older With Atrial Fibrillation: Post Hoc Analysis of the ENGAGE AF-TIMI 48 Randomized Clinical TrialAndré Zimerman, Eugene Braunwald, Jan Steffel, et al.
Circulation. Arrhythmia and Electrophysiology|January 13, 2017
Stroke and Mortality Risk in Patients With Various Patterns of Atrial Fibrillation: Results From the ENGAGE AF-TIMI 48 Trial (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48)Mark S Link, Robert P Giugliano, Christian T Ruff, et al.
Journal of the American Heart Association|October 30, 2018
Efficacy and Safety of Edoxaban in Patients With Active Malignancy and Atrial Fibrillation: Analysis of the ENGAGE AF - TIMI 48 TrialChristina L Fanola, Christian T Ruff, Sabina A Murphy, et al.
Journal of the American Heart Association|July 2, 2017
Digoxin Use and Subsequent Clinical Outcomes in Patients With Atrial Fibrillation With or Without Heart Failure in the ENGAGE AF-TIMI 48 TrialAlon Eisen, Christian T Ruff, Eugene Braunwald, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|November 6, 2019
Efficacy and safety of edoxaban compared with warfarin according to the burden of diseases in patients with atrial fibrillation: insights from the ENGAGE AF-TIMI 48 trialAndré M Nicolau, Ramon Corbalan, Jose C Nicolau, et al.
European Heart Journal|March 24, 2021
Serial assessment of biomarkers and the risk of stroke or systemic embolism and bleeding in patients with atrial fibrillation in the ENGAGE AF-TIMI 48 trialKazuma Oyama, Robert P Giugliano, David D Berg, et al.
Lancet (London, England)|December 10, 2013
Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trialsChristian T Ruff, Robert P Giugliano, Eugene Braunwald, et al.
Heart (British Cardiac Society)|October 31, 2022
Outcomes and drivers of inappropriate dosing of non-vitamin K antagonist oral anticoagulants (NOACs) in patients with atrial fibrillation: a systematic review and meta-analysisValeria Caso, Joris R de Groot, Marcelo Sanmartin Fernandez, et al.
Pageof 20

Showing results (101-110 of 193) with videos related to

Sort By:
Pageof 20
European Heart Journal|February 18, 2015
Edoxaban vs. warfarin in vitamin K antagonist experienced and naive patients with atrial fibrillation†Michelle L O'Donoghue, Christian T Ruff, Robert P Giugliano, et al.
Circulation|October 11, 2019
Comparison of Events Across Bleeding Scales in the ENGAGE AF-TIMI 48 TrialBrian A Bergmark, Pieter W Kamphuisen, Stephen D Wiviott, et al.
JAMA Cardiology|July 10, 2024
Dose Reduction of Edoxaban in Patients 80 Years and Older With Atrial Fibrillation: Post Hoc Analysis of the ENGAGE AF-TIMI 48 Randomized Clinical TrialAndré Zimerman, Eugene Braunwald, Jan Steffel, et al.
Circulation. Arrhythmia and Electrophysiology|January 13, 2017
Stroke and Mortality Risk in Patients With Various Patterns of Atrial Fibrillation: Results From the ENGAGE AF-TIMI 48 Trial (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48)Mark S Link, Robert P Giugliano, Christian T Ruff, et al.
Journal of the American Heart Association|October 30, 2018
Efficacy and Safety of Edoxaban in Patients With Active Malignancy and Atrial Fibrillation: Analysis of the ENGAGE AF - TIMI 48 TrialChristina L Fanola, Christian T Ruff, Sabina A Murphy, et al.
Journal of the American Heart Association|July 2, 2017
Digoxin Use and Subsequent Clinical Outcomes in Patients With Atrial Fibrillation With or Without Heart Failure in the ENGAGE AF-TIMI 48 TrialAlon Eisen, Christian T Ruff, Eugene Braunwald, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|November 6, 2019
Efficacy and safety of edoxaban compared with warfarin according to the burden of diseases in patients with atrial fibrillation: insights from the ENGAGE AF-TIMI 48 trialAndré M Nicolau, Ramon Corbalan, Jose C Nicolau, et al.
European Heart Journal|March 24, 2021
Serial assessment of biomarkers and the risk of stroke or systemic embolism and bleeding in patients with atrial fibrillation in the ENGAGE AF-TIMI 48 trialKazuma Oyama, Robert P Giugliano, David D Berg, et al.
Lancet (London, England)|December 10, 2013
Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trialsChristian T Ruff, Robert P Giugliano, Eugene Braunwald, et al.
Heart (British Cardiac Society)|October 31, 2022
Outcomes and drivers of inappropriate dosing of non-vitamin K antagonist oral anticoagulants (NOACs) in patients with atrial fibrillation: a systematic review and meta-analysisValeria Caso, Joris R de Groot, Marcelo Sanmartin Fernandez, et al.
Pageof 20